22 completed, 7 terminated, 6 unknown, 2 not yet recruiting. 41 Phase 1, 13 Phase 2.
Follow Arsenic Trioxide: new trials by email Literature Review of Arsenic Trioxide trials Research Report on Arsenic Trioxide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome Allogeneic Hematopoietic Stem Cell Transplantation, Arsenic Trioxide, Biospecimen Collection - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-11-01 | 2026-07-30 |
| ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma. ATRA, Arsenic Trioxide (ATO), Gemcitabine - Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Not yet recruiting | Daniel Breadner | 10 | 2026-02-15 | 2026-01-16 |
| Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS) Arsenic Trioxide (ATO) - Low-risk Myelodysplastic Syndromes | Phase 1 | Recruiting | Groupe Francophone des Myelodysplasies | 24 | 2025-07-22 | 2026-09-10 |
| Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia Treatment A: Arsenic Trioxide (ATO) Intravenous, Treatment B: SDK001 (Arsenic Trioxide Oral solution) under faster state, Treatment C: SDK001 (Arsenic Trioxide Oral solution) under fed state - Acute Promyelocytic Leukemia (APL) | Phase 1 | Completed | SDK Therapeutics, Inc. | 12 | 2025-03-11 | 2025-11-18 |
| Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL Arsenic trioxide, all-trans retinoic acid - Promyelocytic Leukemia | Phase 1 / Phase 2 | Unknown | Hospital Universitario Dr. Jose E. Gonzalez | 15 | 2022-07-01 | 2022-10-26 |
| A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia SY-2101, Arsenic Trioxide - Acute Promyelocytic Leukemia | Phase 1 | Suspended | Syros Pharmaceuticals | 16 | 2021-09-17 | 2024-01-23 |
| The Effect of Arsenic Trioxide on Eliminating HIV-1 Reservoir Combined With cART Arsenic Trioxide - HIV/AIDS | Phase 1 | Unknown | Guangzhou 8th People's Hospital | 20 | 2019-04-01 | 2022-09-14 |
| Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid All-trans retinoic acid, Arsenic Trioxide, Realgar-Indigo naturalis formula - Acute Myeloid Leukemia | Phase 1 | Unknown | First Affiliated Hospital Xi'an Jiaotong University | 30 | 2019-02-03 | 2022-03-28 |
| Mutant p53-based Personalized Trial Using Decitabine and Arsenic Trioxide on AML/MDS Decitabine, Arsenic Trioxide - P53 Mutation, Myeloid Malignancy | Phase 1 | Unknown | Ruijin Hospital | 5 | 2018-01-10 | 2022-11-04 |
| Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia Cytarabine, all-trans retinoic acid, Arsenic Trioxide - AML | Phase 1 / Phase 2 | Enrolling by invitation | Institute of Hematology & Blood Diseases Hospital, China | 80 | 2017-02-08 | 2025-05-30 |
| Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI Icotinib, Arsenic trioxide - Non-small Cell Lung Cancer | Phase 1 | Unknown | Betta Pharmaceuticals Co., Ltd. | 9 | 2014-01-01 | 2015-03-13 |
| Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma arsenic trioxide - Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer | Phase 1 / Phase 2 | Completed | Stanford University | 5 | 2013-04-01 | 2018-06-08 |
| Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) Arsenic trioxide - Chronic Myelogenous Leukemia | Phase 1 | Terminated | Beth Israel Deaconess Medical Center | 7 | 2011-09-01 | 2018-09-06 |
| Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis Arsenic Trioxide, Ascorbic Acid, Laboratory Biomarker Analysis - Essential Thrombocythemia, Polycythemia Vera | Phase 1 | Terminated | Roswell Park Cancer Institute | 5 | 2010-04-01 | 2022-07-22 |
| Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia Tamibarotene, Arsenic trioxide - Acute Promyelocytic Leukemia | Phase 1 | Terminated | Northwestern University | 4 | 2009-10-01 | 2013-10-30 |
| Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma Arsenic Trioxide, Ascorbic Acid and Bortezomib - Multiple Myeloma | Phase 1 | Terminated | Duke University | 25 | 2008-07-01 | 2014-01-08 |
| Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia Arsenic Trioxide, Decitabine - Myelodysplastic Syndromes and Leukemia, Myeloid, Acute | Phase 1 | Completed | Washington University School of Medicine | 13 | 2008-05-01 | 2013-06-04 |
| Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma arsenic trioxide, temozolomide, adjuvant therapy - Brain and Central Nervous System Tumors | Phase 1 | Completed | City of Hope Medical Center | 18 | 2008-04-01 | 2010-08-11 |
| Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma Arsenic trioxide, Bortezomib, Melphalan - Multiple Myeloma and Plasma Cell Neoplasm | Phase 1 | Withdrawn | University of Miami | 2007-06-01 | 2016-12-15 | |
| Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes arsenic trioxide, azacitidine - Leukemia, Myelodysplastic Syndromes | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 1 | 2007-02-01 | 2020-07-31 |
Showing 20 of 41. Sign in to see all of them.
Leukemia (10) · Multiple Myeloma (9) · Leukemia, Myeloid, Acute (7) · Myelodysplastic Syndromes (6) · Neoplasms, Plasma Cell (6) · Leukemia, Promyelocytic, Acute (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Astrocytoma (3) · Blast Crisis (3) · Burkitt Lymphoma (3) · Central Nervous System Neoplasms (3) · Glioblastoma (3) · Gliosarcoma (3) · Lymphoma (3) · Anemia, Refractory, with Excess of Blasts (2)
Memorial Sloan Kettering Cancer Center (3) · National Cancer Institute (NCI) (3) · University of Miami (3) · Washington University School of Medicine (3) · M.D. Anderson Cancer Center (2) · Northwestern University (2) · Roswell Park Cancer Institute (2) · Stanford University (2) · Barbara Ann Karmanos Cancer Institute (1) · Beth Israel Deaconess Medical Center (1) · Betta Pharmaceuticals Co., Ltd. (1) · City of Hope Medical Center (1) · Daniel Breadner (1) · Duke University (1) · First Affiliated Hospital Xi'an Jiaotong University (1)
United States (32) · China (5) · Canada (2) · Australia (1) · France (1) · Hong Kong (1) · Mexico (1)
Muzaffar H. Qazilbash, MD (2) · Steven Soignet, MD (2) · Bach Ardalan, MD (1) · Bart L. Scott, MD (1) · Cristina Gasparetto, MD (1) · Daniel Breadner (1) · David E Avigan, MD (1) · Ellin Berman, MD (1) · Eunice Wang, MD (1) · Frank M. Balis, MD (1) · Gail Roboz, M.D. (1) · Gary J. Schiller, MD (1) · Huaiyu Wang, Dr. (1) · Iris Catrice Gibbs (1) · Jana Portnow, MD (1)
PMID 12473574, PMID 17959855, PMID 21815182, PMID 40020161
P30CA006973 (1), P30CA016056 (1), P30CA022453 (1), P30CA033572 (1), U01CA062475 (1), U01CA062505 (1)